Thrombocythemia, Essential
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Contrarily, DNA methylation genes (DNMT3A, IDH1, IDH2 and TET2) were mutated most often in PV (0·5) and less frequently in ET (0·23) and PMF (0·20), but without reaching statistical significance.
|
27447873 |
2016 |
Thrombocythemia, Essential
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as "TET2-first patients"), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ("JAK2-first patients") had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro.
|
25671252 |
2015 |
Thrombocythemia, Essential
|
0.360 |
Biomarker
|
disease |
ORPHANET |
TET2 mutations in Ph-negative myeloproliferative neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings.
|
23781511 |
2013 |
Thrombocythemia, Essential
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
Clonality investigation including mutational status of MPL, TET2, and ASXL1 genes and human androgen receptor (HUMARA) assay was performed in 73 JAK2V617F-negative cases out of 186 subjects consecutively diagnosed with ET in a single institution, at diagnosis or during follow-up.
|
22706669 |
2012 |
Thrombocythemia, Essential
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
We investigated a group of pediatric patients diagnosed either with essential thrombocythemia (ET; N = 9) or polycythemia vera (PV; N = 4) according to WHO criteria (median age = 10 years; range 1.5-15 years) in whom direct sequencing was performed for the existence of genetic alterations in JAK2, MPL, TET2, ASXL1, CBL, IDH1, and IDH2.
|
22106054 |
2012 |
Thrombocythemia, Essential
|
0.360 |
PosttranslationalModification
|
disease |
BEFREE |
In the primary marrow samples, methylation of TET2 occurred in two (5.9%) patients with essential thrombocythaemia (4.4% of all patients), both without JAK2 V617 mutation, but not in polycythaemia vera or primary myelofibrosis.
|
20671051 |
2010 |
Thrombocythemia, Essential
|
0.360 |
Biomarker
|
disease |
ORPHANET |
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
|
19262601 |
2009 |
Thrombocythemia, Essential
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
TET2 mutations were mainly observed (10 of 12) in patients with primary myelofibrosis or patients with polycythemia vera or essential thrombocythemia who secondarily evolved toward myelofibrosis or acute myeloid leukemia.
|
19564637 |
2009 |